CHD CHD CHD Congenital Heart Disease 1747-0803 1747-079X Tech Science Press USA 70042 10.32604/chd.2025.070042 Correction Correction: Efficacy of Intravenous Treprostinil in High-Risk Single Ventricle Patients Undergoing Glenn Procedure Correction: Efficacy of Intravenous Treprostinil in High-Risk Single Ventricle Patients Undergoing Glenn Procedure Correction: Efficacy of Intravenous Treprostinil in High-Risk Single Ventricle Patients Undergoing Glenn Procedure Wang Xiaofeng 1 # Chen Xingwei 2 # Wang Shilin 1 Li Xia 1 Lu Zhongyuan 1 Wang Wenlong 1 Wang Xu 1 fwpicu@163.com Department of Pediatric Intensive Care Unit, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China Department of Pharmacy, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China Corresponding Author: Xu Wang. Email: fwpicu@163.com

#These authors contributed equally to this paper

 2025 11 7 2025 20 3 401 402 07 7 2025 07 7 2025 © 2025 The Authors. 2025 Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article “Efficacy of Intravenous Treprostinil in High-Risk Single Ventricle Patients Undergoing Glenn Procedure” by Xiaofeng Wang, Xingwei Chen, Shilin Wang, Xia Li, Zhongyuan Lu, Wenlong Wang, Xu Wang (Congenital Heart Disease, 2024, vol. 19, no. 5, pp. 489–498. DOI:10.32604/chd.2024.054441, URL: https://www.techscience.com/chd/v19n5/59166), an error was identified in the reporting of statistical values in Table 1 and Table 4. Some p-values were incorrectly shown as “1.0”. The correct values are “>0.999”. The authors apologize for this oversight and present the corrected tables below.

Demographic and surgical characteristics (revised).

Variable Overall (n = 28) Group 1 (n = 14) Group 2 (n = 14) p-Value
Age (years) 5.3 (0.9, 8) 6.7 (2.2, 10.5) 4.0 (0.7, 8) 0.205
Weight (kg) 15.3 (7.9, 21.3) 18.1 (9.8, 36.6) 8.6 (7.6, 19.5) 0.073
Heterotaxy syndrome (case, %) 4 (14) 3 (21) 1 (7) 0.589
Preoperative mPAP (mmHg) 17 ± 3 17 ± 3 18 ± 4 0.813
Cardiopulmonary bypass (min) 159 (86, 189) 165 (75, 189) 142 (98, 203) 0.554
Aortic cross-clamp (min) 83 (66, 113) 101 (63, 123) 80 (71, 92) 0.503
Other surgeries (case, %) 21 (75) 10 (71) 11 (79) >0.999
Intraoperative mPAP (mmHg) 17 ± 3 17 ± 3 18 ± 3 0.292

Note: mPAP: mean pulmonary arterial pressure.

Postoperative recovery (revised).

Overall (n = 28) Group 1 (n = 14) Group 2 (n = 14) p-Value
Mechanical ventilation duration (h) 47 (23, 122) 59 (22, 139) 28 (23, 123) 0.713
ICU length of stay (days) 9 (4, 18) 11 (4, 21) 7 (4, 13) 0.381
Postoperative length of stay (days) 21 (15, 33) 29 (19, 47) 18 (11, 22) 0.021
Duration of chest tube placement (days) 7 (6, 15) 7 (6, 18) 7 (6, 12) 0.762
Chest tube drainage volume (mL/kg) 31 (12, 88) 32 (10, 71) 29 (11, 101) 0.662
Thromboembolic events (cases, %) 3 (11) 2 (14) 1 (7) >0.999
Tachycardia (cases, %) 12 (43) 6 (43) 6 (43) >0.999
Renal replacement therapy (cases, %) 2 (7) 1 (7) 1 (7) >0.999
Tracheal re-intubations (cases, %) 4 (14) 3 (21) 1 (7) 0.589
Tracheostomy (cases, %) 0 (0) 0 (0) 0 (0) NA
Mortality (cases, %) 3 (11) 1 (7) 2 (14) >0.999
Side effects (cases, %) 0 (0) 0 (0) 0 (0) NA

The authors apologize for any inconvenience caused and affirm that the scientific conclusions remain unaffected. This correction has been reviewed and approved by the Editors-in-Chief of Congenital Heart Disease. The original article has been updated accordingly.